NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited.
Market Cap | 1.431 Billion | Shares Outstanding | 126.303 Million | Avg 30-day Volume | 734.944 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 2.1566 | Debt to Equity | 0.5278 | EBITDA | -102.893 Million |
Price to Book Value | 1.0576 | Operating Margin | -34.7872 | Enterprise Value | 1.162 Billion |
Current Ratio | 7.098 | EPS Growth | -4.556 | Quick Ratio | 6.536 |
1 Yr BETA | 1.8383 | 52-week High/Low | 23.78 / 6.0 | Profit Margin | -32.8776 |
Operating Cash Flow Growth | -8432.6403 | Altman Z-Score | 1.0671 | Free Cash Flow to Firm | -98.707 Million |
Earnings Report | 2023-02-22 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
HARRIS MELODY PRESIDENT, ENTERPRISE OPS |
|
309,838 | 2023-01-01 | 2 |
DIETER CYNTHIA J CHIEF ACCOUNTING OFFICER |
|
64,569 | 2022-12-31 | 4 |
SHERMAN JEFFREY SCOTT CHIEF FINANCIAL OFFICER |
|
0 | 2022-12-05 | 2 |
STONE WARREN PRESIDENT, CLINICAL SERVICES |
|
255,319 | 2022-12-01 | 2 |
|
0 | 2022-11-03 | 2 | |
OLIVO ALICIA C GENERAL COUNSEL |
|
40,999 | 2022-10-18 | 1 |
SMITH CHRISTOPHER M CHIEF EXECUTIVE OFFICER |
|
0 | 2022-08-15 | 2 |
SHOLEHVAR DAVID PRESIDENT, CLINICAL SERVICES |
|
135,414 | 2022-08-01 | 3 |
KULKARNI SHASHIKANT PRESIDENT OF LAB OPERATIONS |
|
206,005 | 2022-08-01 | 3 |
|
82,716 | 2022-06-10 | 1 | |
|
33,006 | 2022-06-10 | 1 | |
|
80,326 | 2022-06-10 | 2 | |
|
135,763 | 2022-06-10 | 1 | |
|
42,379 | 2022-06-10 | 1 | |
|
50,067 | 2022-06-10 | 1 | |
|
40,238 | 2022-06-10 | 1 | |
SIKRI VISHAL PRESIDENT AND CCO, INIVATA |
|
467,567 | 2022-06-01 | 2 |
BONELLO WILLIAM CHIEF FINANCIAL OFFICER |
|
439,990 | 2022-04-28 | 4 |
BROWN DOUGLAS MATTHEW CHIEF STRATEGY OFFICER |
|
315,598 | 2022-04-01 | 2 |
CARDOZA GEORGE PRESIDENT & COO, LAB OPS |
|
927,553 | 2022-03-01 | 1 |
GILBERT HALLEY E CHIEF LEGAL OFFICER |
|
313,350 | 2022-03-01 | 1 |
MALLON MARK CHIEF EXECUTIVE OFFICER |
|
866,844 | 2022-03-01 | 1 |
WALLAR GINA M PRESIDENT, PHARMA SERVICES |
|
110,703 | 2022-03-01 | 1 |
MCKENZIE KATHRYN B CHIEF SUSTAINABILITY/RISK OFCR |
|
193,840 | 2022-01-11 | 0 |
BALLIET JENNIFER VP AND CHIEF CULTURE OFFICER |
|
136,052 | 2021-12-30 | 0 |
MORRIS CLIVE PRESIDENT OF INIVATA |
|
95,137 | 2021-12-30 | 0 |
|
48,829 | 2021-12-22 | 0 | |
|
3,440,448 | 2021-08-01 | 0 | |
SHOVLIN ROBERT J. PRESIDENT, CLINICAL SERVICES |
|
264,442 | 2021-05-25 | 0 |
WEISS LAWRENCE MARTIN CHIEF MEDICAL OFFICER |
|
215,224 | 2021-04-22 | 0 |
PEDULLA DENISE E GENERAL COUNSEL |
|
194,849 | 2021-03-01 | 0 |
|
1,386,451 | 2021-01-07 | 0 | |
|
66,800 | 2020-11-16 | 0 | |
VIRAG SHARON CHIEF FINANCIAL OFFICER |
|
10,944 | 2019-03-01 | 0 |
|
No longer subject to file | 2018-12-14 | 0 | |
BRODIE STEVEN G. VP - PHARMA OPERATIONS |
|
45,953 | 2018-10-22 | 0 |
ROSS STEVEN A CIO |
|
9,000 | 2018-05-10 | 0 |
BYWATER STEPHANIE K CHIEF COMPLIANCE OFFICER |
|
528 | 2018-05-01 | 0 |
|
359,474 | 2017-05-25 | 0 | |
ALBITAR MAHER CHIEF MEDICAL OFFICER |
|
60,692 | 2017-04-28 | 0 |
|
0 | 2016-02-17 | 0 | |
MACHULCZ MARK ALAN VICE PRESIDENT OF OPERATIONS |
|
0 | 2016-01-28 | 0 |
HOREL ROBERT H. VICE PRESIDENT GM PATHLOGIC |
|
51,218 | 2015-12-29 | 0 |
JONES STEVEN C EXECUTIVE VP OF FINANCE |
|
3,886,629 | 2015-11-25 | 0 |
|
1,821,650 | 2014-12-04 | 0 | |
GASPARINI ROBERT P CHIEF SCIENCE OFFICER |
|
8,439 | 2014-05-22 | 0 |
|
No longer subject to file | 2013-05-13 | 0 | |
SMITS MARK W CHIEF COMMERCIAL OFFICER |
|
6,667 | 2011-05-18 | 0 |
|
8,191,550 | 2011-05-02 | 0 | |
MILLER MARYDAWN VICE PRESIDENT OF IT |
|
0 | 2011-05-02 | 0 |
DVONCH JEROME J PRINICPAL ACCOUNTING OFFICER |
|
0 | 2011-05-02 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-04 17:39:53 -0500 | 2023-01-01 | A | 108,225 | a | 108,225 | direct | 0.7609 | 12.8261 | 14.2391 | 5 | 0.0 | 1 | ||||
2023-01-04 17:39:53 -0500 | 2023-01-01 | A | 201,613 | a | 201,613 | direct | ||||||||||
2023-01-04 17:40:45 -0500 | 2022-12-31 | F | 959 | d | 30,762 | direct | 0.7609 | 12.8261 | 14.2391 | 5 | 0.0 | 1 | ||||
2022-12-07 20:47:17 -0500 | 2022-12-05 | A | 44,603 | a | 44,603 | direct | -2.7341 | -10.1906 | -4.3082 | 0.0 | 1 | -26.0978 | 14 | |||
2022-12-07 20:47:17 -0500 | 2022-12-05 | A | 89,206 | a | 133,809 | direct | -2.7341 | -10.1906 | -4.3082 | 0.0 | 1 | -26.0978 | 14 | |||
2022-12-07 20:47:17 -0500 | 2022-12-05 | A | 249,169 | a | 249,169 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
NEOGENOMICS INC NEO | 2023-01-31 20:15:03 UTC | 4.0352 | 0.2848 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 19:45:03 UTC | 4.0352 | 0.2848 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 19:15:04 UTC | 4.0352 | 0.2848 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 18:45:03 UTC | 4.0352 | 0.2848 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 18:15:03 UTC | 4.0352 | 0.2848 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 17:45:03 UTC | 4.0352 | 0.2848 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 17:15:04 UTC | 4.0352 | 0.2848 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 16:45:04 UTC | 4.0592 | 0.2608 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 16:15:03 UTC | 4.0592 | 0.2608 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 15:45:03 UTC | 4.0592 | 0.2608 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 15:15:04 UTC | 4.0592 | 0.2608 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 14:45:03 UTC | 4.0592 | 0.2608 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 14:15:03 UTC | 4.0592 | 0.2608 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 13:45:03 UTC | 4.07 | 0.25 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 13:15:04 UTC | 4.07 | 0.25 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-31 12:45:03 UTC | 4.07 | 0.25 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-30 22:15:03 UTC | 4.07 | 0.25 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-30 21:45:04 UTC | 4.07 | 0.25 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-30 21:15:03 UTC | 4.07 | 0.25 | 3800000 |
NEOGENOMICS INC NEO | 2023-01-30 20:45:03 UTC | 4.07 | 0.25 | 3800000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Master Neutral Fund | NEO | -97.0 shares, $-3578.33 | 2020-09-30 | N-PORT |
RUSSELL INVESTMENT CO- U.S. Dynamic Equity Fund | NEO | -5237.0 shares, $-277665.74 | 2021-01-31 | N-PORT |
Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund | NEO | -2100.0 shares, $-94857.0 | 2021-06-30 | N-PORT |
SCHWAB CAPITAL TRUST- Schwab Hedged Equity Fund | NEO | -3377.0 shares, $-155679.7 | 2021-07-31 | N-PORT |
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio | NEO | -42400.0 shares, $-2045376.0 | 2021-09-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | NEO | -412.0 shares, $-3547.32 | 2022-09-30 | N-PORT |
First Trust Exchange-Traded Fund III- First Trust Long/Short Equity ETF | NEO | -11519.0 shares, $-87602.0 | 2022-10-31 | N-PORT |